Drug intelligence / Profile preview

ZL-65

Development stage: Phase 1
Lead developer: Zenitar
Modality: Small Molecules

Overview

ZL-65 is a small molecule drug candidate developed by Chengdu Zenitar Biomedical Technology. It is currently in preclinical development and is being investigated for the treatment of immune system diseases, nervous system diseases, and congenital disorders. The primary indications under investigation include cryopyrin-associated periodic syndromes (CAPS), multiple sclerosis, autoinflammatory disease, gout, and nonalcoholic steatohepatitis. The precise mechanism of action or molecular targets have not been publicly disclosed as of the latest available update[1].

Beyond the preview

Go deeper on ZL-65.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZL-65.

Explore the full profile